Recursion Pharmaceuticals

RXRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.125 B

$3.97 +3.65%

Close of 21 Sept 2026

Revenue

$74.7M

#2604 by revenue

Earnings

-$644.8M

Loss-making

Shares outstanding

535,342,170

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#30Biocryst PharmaceuticalsBCRX$2.24B
#31Adma BiologicsADMA$2.13B
#32Recursion PharmaceuticalsRXRX$2.13B
#33Kodiak SciencesKOD$2.04B
#34VericelVCEL$2.03B

What if Recursion Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$56,550.85

Per share 14,245× higher

Bitcoin $1.72T

$3,212.53

Per share 809× higher

Nvidia $5.48T

$10,236.18

Per share 2,578× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Recursion Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.